Latest news with #DYN
Business Insider
3 days ago
- Business
- Business Insider
Dyne Therapeutics assumed with an Outperform at Raymond James
Raymond James analyst Martin Auster assumed coverage of Dyne Therapeutics (DYN) with an Outperform rating and $37 price target as part of a broader research note on selection Biotech names. Risk/reward skews favorably across the sector, though while companies with high PoS – probability of success – lead assets allow for higher conviction, highly attractive skews on less de-risked assets may deliver the most outsized returns, the analyst tells investors in a research note. For the stock, the firm notes that while it is trading at an enterprise value below $1B, Dyne's increasingly clinically-validated FORCE platform offers a compelling long-term risk-reward with proof of concept established on two assets in valuable, high unmet need markets, Raymond James added. Confident Investing Starts Here:
Yahoo
12-03-2025
- Business
- Yahoo
BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating
BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price target, suggesting a strong upside from the company's current share price of $12.03. Warning! GuruFocus has detected 3 Warning Signs with DYN. Using its TfR1-targeted delivery system, Dyne focuses in creating therapies for neuromuscular disorders. Key clinical initiatives of the business include its myotonic dystrophy type 1 therapy, now in Phase I/II studies, and its Duchenne muscular dystrophy treatment, which might be commercialized by 2026. The FDA's ruling on Dyne's DM1 therapy is a main determinant of her market course. The date of clearance might affect its capacity to access the market in relation to Avidity, a rival company in the field. Analysts advise Dyne may set itself apart by providing a therapy with advantages for central nervous systems. With a current ratio of 15.6 and a market capitalization of $1.37 billion, the firm shows good liquidity. With a beta of 1.11, it has only little connection with the larger market. Some analysts see a possible buying chance in the stock as it has down 51.19% year to date. Important forthcoming events include possibly accelerated approval applications for DYNE-251 and DYNE-101 in 2026. Early January 2025 will also include results from the DM1 Phase 1/2 ACHIEVE study, which will offer information on functional outcomes and splicing repair. Investor mood is still divided; substantial upward potential depends on clinical benchmarks and regulatory clearance routes. Although concerns still relate to regulatory choices and competitive market positioning, analysts stress the company's strong liquidity and pipeline developments. This article first appeared on GuruFocus. Sign in to access your portfolio
